Head-To-Head Comparison: Finch Therapeutics Group (NASDAQ:FNCH) vs. AIM ImmunoTech (NYSE:AIM)

Finch Therapeutics Group (NASDAQ:FNCH) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Valuation & Earnings

This table compares Finch Therapeutics Group and AIM ImmunoTech’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	$110,000.00	38.06	-$114.65 million	($47.67)	-0.05
AIM ImmunoTech	$140,000.00	164.31	-$19.44 million	($0.43)	-1.10

AIM ImmunoTech has higher revenue and earnings than Finch Therapeutics Group. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Finch Therapeutics Group has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Finch Therapeutics Group and AIM ImmunoTech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0	0	0	0	N/A
AIM ImmunoTech	0	0	0	0	N/A

Finch Therapeutics Group currently has a consensus price target of $210.00, indicating a potential upside of 7,976.61%. Given Finch Therapeutics Group’s higher possible upside, equities analysts clearly believe Finch Therapeutics Group is more favorable than AIM ImmunoTech.

Profitability

This table compares Finch Therapeutics Group and AIM ImmunoTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-136.63%	-57.40%
AIM ImmunoTech	-10,764.25%	-67.33%	-59.60%

Insider & Institutional Ownership

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Finch Therapeutics Group beats AIM ImmunoTech on 6 of the 11 factors compared between the two stocks.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.